Adalta Ltd. is gearing up to begin phase II trials of its lead i-body candidate, AD-214, in idiopathic pulmonary fibrosis (IPF), but it is hoping to find a pharma partner to fund the trials.

The common pathological pathway in progressive chronic kidney disease (CKD) is tissue fibrosis and chemokine receptor type 4 (CXCR4) plays a key role in the development of fibrosis.